Impact of Polymorphism in Drug Discovery and Development
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 May 2019) | Viewed by 461
Special Issue Editors
Interests: diffraction techniques; structure elucidation; conformation of bioactive compounds; antitubercular and anticancer agents; metal complexes, protein–protein interaction inhibitors; enzymatic inhibitors; multi-target drugs
Special Issues, Collections and Topics in MDPI journals
Interests: protein–protein interaction inhibitors; enzyme inhibitors; multi-target drugs; anticancer agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce that submissions for the Molecules Special Issue “Polymorphism in Drug Discovery and Development” are now open.
With the continuous development of new drug delivery technologies, complex situations arise such as difficult cases of polymorph selection and the co-crystallization of different molecules. Poly- and pseudo-polymorphs (i.e., co-crystals characterized as hydrates (solvent trapped), solvates (solvent present), and clathrates (molecules trapped)) are solid crystalline materials able to exist in two or more crystalline forms with different arrangements or conformations of the constituents in the crystal lattice. The API (active pharmaceutical ingredient) in the polymorphs or in the pseudo-polymorphs, although chemically the same, presents different physicochemical properties (e.g., solubility, melting point, particle size, dissolution rate, hygroscopicity, and others), which in turn result in drug differences (i.e., in efficacy, bioavailability, and even toxicity). As poly- and pseudo-morphism are very common amongst drugs, understanding the basic properties of pharmaceutical solids is fundamental to drug discovery, development, clinical studies, manufacturing, processing, problem investigations, and stability.
This issue will cover multiple aspects of poly- and pseudo-polymorphs, including their preparation, characterization by means of both experimental and calculation techniques, case study, and their applications in drug discovery and development. Regular articles are welcome, as are perspectives and, when applicable, reviews.
Dr. Fiorella Meneghetti
Prof. Dr. Daniela Barlocco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- polymorphism screening
- drug solubility
- crystallization
- crystallography
- pharmaceutical solids
- phase transformation
- structure–property relationship
- stability
- bioavailability
- TGA
- XRD
- DSC
- FTIR
- NMR
- regulatory issues
